William E. Rote
Chief Research Officer at Travere Therapeutics, Inc. (TVTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 63,907130,488 held (−33%) | $61.99 | $4.0M | -15.9% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 29,021101,467 held (−22%) | $62.66 | $1.8M | -16.8% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 3,00098,467 held (−3%) | $63.65 | $191K | -18.1% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 27098,197 held (−0%) | $65.31 | $18K | -20.2% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 65,104145,943 held (−31%) | $63.12 | $4.1M | -17.4% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 47,74698,197 held (−33%) | $63.61 | $3.0M | -18.1% |
| May 6SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 2,763115,474 held (−2%) | $43.95 | $121K | +18.6% |
| Apr 23SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 9,100113,987 held (−7%) | $39.09 | $356K | +33.3% |
| Feb 3SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 12,446109,087 held (−10%) | $32.87 | $409K | +58.6% |
| Dec 29SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 60,000101,443 held (−37%) | $40.10 | $2.4M | +30.0% |
- Sell
Chief Research Officer William E. Rote sold $4.0M of TVTX at $61.99 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Research Officer William E. Rote sold $1.8M of TVTX at $62.66 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Research Officer William E. Rote sold $191K of TVTX at $63.65 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Research Officer William E. Rote sold $18K of TVTX at $65.31 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Research Officer William E. Rote sold $4.1M of TVTX at $63.12 — cuts the stake by 31%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Research Officer William E. Rote sold $3.0M of TVTX at $63.61 — cuts the stake by 33%; pre-scheduled 10b5-1 plan sale.